Immunobiology of vasoactive intestinal peptide (VIP)

Immunology Today

Volumn 21, Issue 1, 2000, Pages 7-11

  Pozo, David ^a   Delgado, Mario ^b   Martínez, Carmen ^b   Guerrero, Juan M ^a   Leceta, Javier ^b   Gomariz, Rosa P ^b   Calvo, Juan R ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CD3 ANTIGEN; CD4 ANTIGEN; CELL SURFACE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE RECEPTOR; MESSENGER RNA; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ARTICLE; CELL PROTECTION; HUMAN; HUMAN CELL; HYPOPHYSIS; IMMUNOBIOLOGY; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MITOGENESIS; NEUROENDOCRINE SYSTEM; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; THYMOCYTE;

EID: 0002587195     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(99)01525-X     Document Type: Short Survey

References (33)

1. Blalock J.E. The syntax of immune-neuroendocrine communication. Immunol. Today. 15:1994;504-510.
2. Said S., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 169:1970;1217-1218.
3. Cutz E.et al. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. Nature. 275:1978;661-662.
4. Leceta J.et al. Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv. Neuroimmunol. 6:1996;29-36.
5. Gomariz R.et al. Demonstration of immunoreactivity vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus. Brain Behav. Immun. 4:1990;151-161.
6. Wascheck J.A. Turner A.J. Neuropeptide Gene Expression. 1994;107-132 Portland Press.
7. Martinez C.et al. Regulation of VIP production and secretion by murine lymphocytes. J. Neuroimmunol. 93:1999;126-138.
8. Calvo J.R.et al. Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Adv. Neuroimmunol. 6:1996;39-47.
9. O'Dorisio M.et al. Vasoactive intestinal peptide and neuropeptide modulation of the immune response. J. Immunol. 135:1985;792-796.
10. Tseng T., O'Dorisio M. Goetzl E.J., Specter N.H. Neuroimmune Network: Physiology and Diseases. 1997;105-111 Alan R. Liss.
11. Ishihara T.et al. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron. 8:1992;811-819.
12. Harmar A.J.et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50:1998;265-270.
13. Gomariz R.P.et al. Gene expression of VIP receptor in rat lymphocytes. Biochem. Biophys. Res. Commun. 203:1994;1599-1604.
14. Delgado M.et al. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul. Pept. 62:1996;161-166.
15. Delgado M.et al. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 68:1996;27-38.
16. Cai Y.et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. Endocrinology. 138:1997;2515-2520.
17. Pozo D.et al. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochim. Biophys. Acta. 1359:1997;250-262.
18. Delgado M.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor a transcriptional activation by regulating factor-κB and cAMP response element-binding protein/c-Jun. J. Biol. Chem. 273:1998;31427-31436.
19. 1) receptor stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim. Biophys. Acta. 1357:1997;249-255.
20. Pankhaniya R.et al. Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes. FASEB J. 12:1998;119-127.
21. Grossman Z., Singer A. Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus. Proc. Natl. Acad. Sci. U. S. A. 93:1996;14747-14752.
22. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:1996;61-74.
23. Delgado M.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation. J. Immunol. 162:1999;4685-4696.
24. Martinez C.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukocyte Biol. 63:1998;591-601.
25. Delgado M.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: in vitro and in vivo studies. J. Immunol. 162:1999;2358-2367.
26. Delgado M.et al. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J. Neuroimmunol. 96:1999;167-181.
27. Delgado M.et al. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162:1999;1707-1716.
28. Delgado M.et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. 162:1999;1200-1205.
29. Weinstock J. Vasoactive intestinal peptide regulation of granulomatous inflammation in murine Schistosomiasis mansoni. Adv. Neuroimmunol. 6:1996;95-105.
30. Said S. VIP as a modulator of lung inflammation and airway constriction. Am. Rev. Respir. Dis. 143:1991;22-24.
31. Kalfin R.et al. Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium. J. Pharmacol. Exp. Ther. 268:1994;952-958.
32. Said S.et al. Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;4688-4692.
33. Kratz A.et al. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J. Exp. Med. 183:1996;1461-1472.